0000000000316102

AUTHOR

ŽEljko Debeljak

showing 1 related works from this author

Promoter methylation status of ASC/TMS1/PYCARD is associated with decreased overall survival and TNM status in patients with early stage non-small ce…

2019

Background: Lung cancer is the leading cause of cancer-related death worldwide, with 5-year overall survival less than 15%. Therefore, it is essential to find biomarkers for early detection and prognosis. Aberrant DNA methylation is a common feature of human cancers and its utility is already recognized in cancer management. The aim of this study was to explore the diagnostic and prognostic value of the promoter methylation status of the ASC/TMS1/PYCARD and MyD88 genes, key adaptor molecules in the activation of the innate immune response and apoptosis pathways. Methods: A total of 50 non-small cell lung cancer (NSCLC) patients were enrolled in the study. Methylation of bisulphite converted…

0301 basic medicinebusiness.industrynon-small cell lung cancer (NSCLC)Basic Medical SciencesPromoterPYCARDMethylationmedicine.disease3. Good health03 medical and health sciences030104 developmental biology0302 clinical medicineOncologyCpG site030220 oncology & carcinogenesismedicineCancer researchASC/TMS1/PYCARD ; MyD88 ; methylation status ; association ; overall survival ; TNM ; non-small cell lung cancer (NSCLC)Stage (cooking)Lung cancerbusinessGene
researchProduct